UAB / UMN SPORE in Pancreatic Cancer

六年前，我们的UAB孢子在胰腺癌中的申请部分是通过P-20拨款获得的。在资金有限的情况下，我们的小孢子由两个主要项目、三个核心和一个发展研究计划组成。在最初的资助期间，孢子科学的转化导致了两项I期试验、一项II期试验和一项新的核磁共振成像试验。该孢子的研究人员有88份与孢子项目或胰腺癌有关的出版物。发展研究基金导致了两个主要项目，项目1和项目4在这次续签申请中，以及2名获奖者成为项目的共同领导者。三年前，Vickers博士(孢子皮)成为明尼苏达大学(UMN)的外科主任，我们重组为胰腺癌UAB/UMN联合孢子。联合孢子运作良好，这项建议是我们修订后的全孢子资助竞争性续期(PSO申请)。这项建议有四个主要项目：项目1是利用转基因动物模型中的蛋白质组技术来确定预测早期胰腺癌的生物标记物；项目2是一个延续项目，正在研究多种方法来增强抗DR5单抗在胰腺癌动物模型和患者中的治疗效果；项目3是利用从人胰腺癌(PCA)样本获得的基因组和基因数据以及从PCA小鼠模型中观察到的数据，以了解在这种疾病中驱动转移和治疗耐药性的遗传事件。这些研究将导致I期临床试验；项目4正在设计新的有条件复制的腺病毒载体，靶向胰腺癌干细胞样瘤细胞，用于治疗转移性胰腺癌。四个重要和有效的核心是：1)管理；2)组织资源和分子病理学；3)生物统计学；4)临床管理和试验(宣传性分核心)。我们还请求继续支持我们的发展研究和职业发展项目，其中包括莫尔豪斯医学院和塔斯基吉大学。该应用程序得到了UAB和UMN的强有力的机构支持，优秀的胰腺癌人群，并符合联邦指南。

Six years ago, our UAB SPORE in Pancreatic Cancer application was partially funded via a P-20 grant. With limited funding; our mini-SPORE was composed of 2 major projects, 3 Cores and a Developmental Research Program. During this initial funding period, translation of SPORE science resulted in two phase I trials, one Phase II trial and a novel MRI imaging trial. The investigators of the SPORE have 88 publications relating to SPORE projects or pancreatic cancer. The Developmental Research funding resulted in two major projects, Projects 1, & 4 in this renewal application and 2 awardees becoming Project co-leaders. Three years ago, Dr. Vickers (SPORE PI) became Chairman of Surgery at the University of Minnesota (UMN) and we restructured into a joint UAB/UMN SPORE in Pancreatic Cancer. The joint SPORE has functioned well and this proposal is our amended competitive renewal for full SPORE funding (PSO application). This proposal has 4 major projects: Project 1 is utilizing proteomic techniques in transgenic animal models to identify biomarkers that are predictive of early stage pancreatic cancer; Project 2 is a continuation project which is examining multiple methods to enhance the therapeutic efficacy of anti-DR5 monoclonal antibodies in pancreatic cancer animal models and patients; Project 3 is utilizing genomic and genetic data obtained from human pancreatic cancer (PCa) samples and observations from mouse models of PCa to understand the genetic events that drive metastasis and treatment resistance in this disease. These studies will lead to a phase I clinical trial; Project 4 is engineering novel conditionally replicative adenoviral vectors that target pancreatic cancer stem cell-like tumor cells for the treatment of metastatic pancreatic cancer. The four important and effective Cores are: 1) Administration; 2) Tissue Resource and Molecular Pathology; 3) Biostatistics; and 4) Clinical Management and Trials (Advocacy Sub-Core). We also request support for continuation of our Developmental Research and Career Development Programs which includes Morehouse School of Medicine and Tuskegee University. The application has strong institutional support from UAB and UMN, excellent pancreatic cancer populations and concurrence with federal guidelines.